Log in to save to my catalogue

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant...

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10259758

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

About this item

Full title

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

Publisher

US: Oxford University Press

Journal title

The oncologist (Dayton, Ohio), 2022-12, Vol.27 (12), p.e982-e982

Language

English

Formats

Publication information

Publisher

US: Oxford University Press

Subjects

Subjects and topics

More information

Alternative Titles

Full title

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10259758

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10259758

Other Identifiers

ISSN

1083-7159,1549-490X

E-ISSN

1549-490X

DOI

10.1093/oncolo/oyac207

How to access this item